 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
78 News |  |
- || Zohydro ER (hydrocodone bitartrate extended release) / Pernix
PK/PD data, Journal: Pharmacokinetic and Pharmacodynamic Correlations From 2 Studies Evaluating Abuse Potential of Hydrocodone Extended-Release Tablets. (Pubmed Central) - Mar 24, 2020
In a crossover study design, subjects received intact hydrocodone ER, finely milled hydrocodone ER, and hydrocodone powder in solution in the oral study and finely milled hydrocodone ER, hydrocodone powder, and finely milled Zohydro® ER in the intranasal study...For Overall Drug Liking and Take Drug Again VAS, ρ values for correlations with PK parameters ranged from 0.2620 to 0.3637. In the intranasal study, no clear correlations between PK and PD parameters were apparent.
- || Zohydro ER (hydrocodone bitartrate extended release) / Pernix
You might get why I want to replace Norco with ZoHydro, to have something with no acet in it. It adds nothing but irritation. Moot point. I can't get anything BUT acet. (Twitter) - Nov 12, 2019
- | Hysingla ER (hydrocodone bitartrate) / Purdue, Vantrela ER (hydrocodone bitartrate) / Teva, Zohydro ER (hydrocodone bitartrate extended release) / Pernix
Journal: Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. (Pubmed Central) - Aug 8, 2019
Incidences of adverse events for intranasal treatments were 52% for hydrocodone ER, 53% for hydrocodone powder, and 61% for HYD-OF. The statistically significant differences between hydrocodone ER vs hydrocodone powder and HYD-OF for the primary drug liking end points indicate a lower intranasal abuse potential with hydrocodone ER in healthy, nondependent, recreational opioid users.
- | Hysingla ER (hydrocodone bitartrate) / Purdue, Zohydro ER (hydrocodone bitartrate extended release) / Pernix
Clinical, Journal: Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain. (Pubmed Central) - May 30, 2019
HYD demonstrated a safety profile typical of µ opioids; nausea, constipation, vomiting, and dizziness were the most frequently reported opioid-related adverse events during the study. In patients with chronic pain who received HYD over a 52-week period, treatment was generally well tolerated and provided effective analgesia among those who rotated from a pain regimen primarily consisting of IR oxycodone.
- | Zohydro ER (hydrocodone bitartrate extended release) / Currax
New P1 trial: Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment (clinicaltrials.gov) - Sep 22, 2014
P1, N=37, Completed, Sponsor: Zogenix, Inc.
- | Zohydro ER (hydrocodone bitartrate extended release) / Currax
New P1 trial: Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment (clinicaltrials.gov) - Sep 19, 2014
P1, N=30, Completed, Sponsor: Zogenix, Inc.
- | Zohydro ER (hydrocodone bitartrate extended release) / Currax
New P2 trial: A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain (clinicaltrials.gov) - Aug 21, 2014
P2, N=37, Completed, Sponsor: Zogenix, Inc.
- ||||| Zohydro ER (hydrocodone bitartrate extended release) / Currax
New P2 trial, Surgery: A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery (clinicaltrials.gov) - Jul 23, 2014
P2, N=241, Completed, Sponsor: Zogenix, Inc.
- | Zohydro ER (hydrocodone bitartrate extended release) / Currax
New P1 trial: To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules (clinicaltrials.gov) - Apr 15, 2014
P1, N=12, Completed, Sponsor: Zogenix, Inc.
- | Zohydro ER (hydrocodone bitartrate extended release) / Currax
New P1 trial: A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER) (clinicaltrials.gov) - Apr 14, 2014
P1, N=30, Completed, Sponsor: Zogenix, Inc.
- ||||| Zohydro ER (hydrocodone bitartrate extended release) / Currax
Enrollment change: Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain (clinicaltrials.gov) - Mar 24, 2014
P3, N=510, Completed, Sponsor: Zogenix, Inc.
In patients with chronic pain who received HYD over a 52-week period, treatment was generally well tolerated and provided effective analgesia among those who rotated from a pain regimen primarily consisting of IR oxycodone. N=302 --> 510
- ||||| Zohydro ER (hydrocodone bitartrate extended release) / Currax
Enrollment change: Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain (clinicaltrials.gov) - Apr 30, 2012
P3, N=424, Completed, Sponsor: Zogenix, Inc.
N=302 --> 510 N=600 --> 424
- ||||||| Zohydro ER (hydrocodone bitartrate extended release) / Currax
Trial completion: Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain (clinicaltrials.gov) - Apr 30, 2012
P3, N=424, Completed, Sponsor: Zogenix, Inc.
N=600 --> 424 Active, not recruiting --> Completed
- ||||||| Zohydro ER (hydrocodone bitartrate extended release) / Currax
Trial completion: Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain (clinicaltrials.gov) - Apr 30, 2012
P3, N=510, Completed, Sponsor: Zogenix, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed